Anderson N L, Esquer-Blasco R, Richardson F, Foxworthy P, Eacho P
Large Scale Biology Corporation, Rockville, Maryland 20850, USA.
Toxicol Appl Pharmacol. 1996 Mar;137(1):75-89. doi: 10.1006/taap.1996.0059.
We have investigated the effects of five peroxisome proliferators (PPs : clofibric acid, DEHP, WY14,643, nafenopin, and LY171883) on the abundances of a large number of proteins in the livers of treated mice at 5- and 35-day time points. LY171883 was investigated at a range of doses, and one of its close structural analogs that is not a peroxisome proliferator (LY163443) was included as a negative control compound. Liver samples were analyzed by quantitative 2-D electrophoresis. Data for a selected set of 107 liver protein spots that respond strongly to at least one of the test compounds was subjected to principal component analysis to search for global protein pattern changes. The first component (PC1) accounted for 51% of the total data variance and was identified as a global measure of peroxisome proliferation by its correlation with enzymatic peroxisomal beta-oxidation. Component PC2 (7%) separated 5- and 35-day exposures, and PC3 (5%) separated groups treated with LY163443 from the rest. We used PC1 as a surrogate for equivalent dose in order to examine the effects of diverse compounds, with widely differing potencies, on a common scale. Analyzed in this way, the data indicate that all the peroxisome proliferators tested produce effects over wide time and dose ranges that fall on or near a single curve. Examination of specific protein responses showed that many proteins individually show a unified response curve, but that curves for different proteins were different. In particular, it appears that some constitutive proteins showing modest inductions with a high dose plateau (such as cytosolic epoxide hydrolase) are inducible at lower doses than some proteins showing very strong, nonplateaued inductions (such as the 80-kDa peroxisomal bifunctional enzyme). The results provide support for a unified receptor-based mechanism controlling the main PP response, but demonstrate that individual responsive genes can show quite different dose-response curves.
我们研究了五种过氧化物酶体增殖剂(PPs:氯贝酸、邻苯二甲酸二(2-乙基己基)酯、WY14643、萘酚平以及LY171883)在5天和35天时间点对经处理小鼠肝脏中大量蛋白质丰度的影响。对LY171883进行了一系列剂量的研究,并将其一种非过氧化物酶体增殖剂的结构类似物(LY163443)作为阴性对照化合物。通过定量二维电泳分析肝脏样本。对一组选定的、对至少一种测试化合物有强烈反应的107个肝脏蛋白质斑点的数据进行主成分分析,以寻找整体蛋白质模式变化。第一主成分(PC1)占总数据方差的51%,通过其与过氧化物酶体β-氧化酶的相关性被确定为过氧化物酶体增殖的整体指标。第二主成分(PC2,占7%)区分了5天和35天的暴露情况,第三主成分(PC3,占5%)将用LY163443处理的组与其他组区分开来。我们使用PC1作为等效剂量的替代指标,以便在同一尺度上研究不同效力的多种化合物的影响。以这种方式分析数据表明,所有测试的过氧化物酶体增殖剂在广泛的时间和剂量范围内产生的影响都落在或接近一条单一曲线。对特定蛋白质反应的研究表明,许多蛋白质各自呈现出统一的反应曲线,但不同蛋白质的曲线不同。特别是,一些组成型蛋白质在高剂量平台期显示出适度诱导(如胞质环氧化物水解酶),其在较低剂量下的诱导性似乎比一些显示出非常强烈的、无平台期诱导的蛋白质(如80 kDa过氧化物酶体双功能酶)更低。这些结果支持了一种基于统一受体的机制来控制主要的PP反应,但表明各个反应基因可以呈现出非常不同的剂量-反应曲线。